Journal
JOURNAL OF MOLECULAR RECOGNITION
Volume 26, Issue 1, Pages 1-9Publisher
WILEY
DOI: 10.1002/jmr.2210
Keywords
ss-amyloid (A ss) peptide; single chain llama anti-A ss antibody; affinity-mass spectrometry; proteolytic excision; proteolytic extraction; A ss(17-28)-epitope
Categories
Funding
- European Union through the network Human Proteome Binders
- EU grant Integrating High Performance Mass Spectrometry with Applications in Life Sciences (MSLife)
Ask authors/readers for more resources
beta-Amyloid (A beta) immunotherapy has become a promising strategy for reducing the level of A beta in brain. New immunological approaches have been recently proposed for rapid, early diagnosis, and molecular treatment of neurodegenerative diseases related to Alzheimer's Disease (AD). The combination of proteolytic epitope excision and extraction and mass spectrometry using digestion with various proteases has been shown to be an efficient tool for the identification and molecular characterization of antigenic determinants. Here, we report the identification of the A beta epitope recognized by the variable domain of single chain llama anti-A beta-antibodies, termed A beta-nanobodies, that have been discovered in the blood of camelids and found to be promising candidates for immunotherapy of AD. The epitope recognized by two A beta-specific nanobodies was identified by proteolytic epitope extraction- and excision-mass spectrometry using a series of proteases (trypsin, chymotrypsin, GluC-protease, and LysC-protease). Matrix-assisted laser desorption ionization mass spectrometric analysis of the affinity elution fraction provided the epitope, A beta(1728), in the mid- to carboxy-terminal domain of A beta, which has been shown to exert an A beta-fibril inhibiting effect. Affinity studies of the synthetic epitope confirmed that the A beta(1728) peptide is the minimal fragment that binds to the nanobodies. The interactions between the nanobodies and full length A beta(140) or A beta-peptides containing or lacking the epitope sequence were further characterized by enzyme linked immunosorbent assay and bioaffinity analysis. Determinations of binding affinities between the A beta-nanobodies and A beta(140) and the A beta(1728) epitope provided KD values of approximately 150 and 700?nmol, respectively. Thus, the knowledge of the epitope may be highly useful for future studies of A beta-aggregation (oligomerization and fibril formation) and for designing new aggregation inhibitors. Copyright (c) 2012 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available